Study on Optimal Treatment Strategy for Elderly Patients With High-risk Complex Aortic Valve Disease

  • STATUS
    Recruiting
  • participants needed
    540
  • sponsor
    Yongjian Wu
Send
Updated on 15 September 2021
See if I qualify

Summary

Aortic valve disease (AVD) is the most common and age-related mortality in elderly patients with valvular heart disease (VHD). Although transcatheter aortic valve replacement (TAVR) has been recommended at a higher level in foreign guidelines, there are still many high-risk and severe elderly patients with VHD who have not received effective treatment because of many complications and untimely medical treatment. Different from Europe and the United States, the majority of patients with bicuspid aortic valve are in China, and the calcification is more serious. The current clinical evaluation system and treatment guidelines can not be effectively applied to the high-risk and complex elderly patients. Therefore, we should train and set up a valvular heart disease team, explore the technical difficulties of TAVR treatment in such patients, establish emergency TAVR operation mechanism, build a clinical evaluation system for high-risk and complex elderly patients with aortic valve disease in China, evaluate the curative effect periodically and further optimize the treatment strategy, so as to improve the quality of life and the meaning of life cycle of elderly patients with VHD in China Great significance.

Details
Condition Aortic Valve Disease
Age 75years - 100years
Clinical Study IdentifierNCT05044377
SponsorYongjian Wu
Last Modified on15 September 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

patients over 75 years old meet one of the following conditions. severe valvular heart disease as defined by echocardiography: #1#aortic stenosis, moderate or above, or valve area 1.0cm2, or maximal jet velocity 4.0m/sec, or mean pressure gradient 40mmHg, #2#aortic regurgitation, moderate or above, or jet width 65% of left ventricular outflow tract, or regurgitant volume
ml/beat, or regurgitant fraction 50%

Exclusion Criteria

Patients cannot be followed up for any reasons. Patients have been enrolled in this study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.